DaVita stock performance snapshot after recent moves

DaVita (DVA) has traded lower recently, with the stock down 0.8% on the day, 1.6% over the past week, and about 26% over the past month. Over the past 3 months it has declined roughly 11%.

Despite this pullback, DaVita still shows a year to date total return of 51.8% and a 1 year total return of 26.6%. Over 3 years and 5 years, total returns are 72.9% and 32.5% respectively. This provides investors with additional context for the recent weakness.

At a share price of $173.82, DaVita has given up part of its strong year to date share price return while still sitting on solid multi year total shareholder returns. This suggests that recent weakness reflects shifting sentiment around future growth and risk rather than a complete change in the longer term story.

If you are weighing DaVita against other opportunities in healthcare, it can help to scan a focused list of companies using advanced technology in the sector, including 41 healthcare AI stocks.

After a sharp pullback yet still strong multi year returns, DaVita now sits at a different entry point for new money than it did a month ago. Does the current valuation still skew the risk reward in buyers’ favor?

Most Popular Narrative: 16.7% Undervalued

Based on the most followed narrative, DaVita's fair value of $208.57 sits above the last close at $173.82, which frames the current pullback as a valuation gap rather than a fully priced story.

The aging population and rising rates of diabetes and hypertension continue to fuel steady underlying demand for dialysis, and management reaffirmed their belief in a return to 2% annual treatment growth over time, suggesting upside to revenue as volumes recover from temporary disruptions.

Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth.

Want to see what underpins that uplift in DaVita's fair value? The narrative leans on a specific mix of volume recovery, margin expansion and a lower future earnings multiple than many investors might assume.

The fair value estimate of $208.57 uses a 7.9% discount rate and blends expected revenue growth, profit margins and risk factors into one forward looking view for DaVita. The result implies a sizeable gap to the current share price but relies on detailed assumptions for future earnings power, valuation multiples and cash generation that investors may wish to test against their own expectations.

Result: Fair Value of $208.57 (UNDERVALUED)

However, DaVita's narrative could be challenged if elevated patient mortality keeps treatment volumes under pressure or if reimbursement updates continue to lag behind underlying cost inflation.

Next Steps

Does this mix of risks and rewards around DaVita match your own read of the story, or does it feel off? Act soon and weigh both sides by reviewing the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond DaVita?

If DaVita is on your radar, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that might suit your goals before the market moves.

• Spot potential value opportunities by reviewing companies highlighted in the 48 high quality undervalued stocks.
• Build a steadier portfolio by checking out stocks featured in the 75 resilient stocks with low risk scores.
• Hunt for potential future standouts by scanning the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.